Cite
HARVARD Citation
Sallman, D. et al. (2021). Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. Journal of clinical oncology. 39 (14), pp. 1584-1594. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Sallman, D. et al. (2021). Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. Journal of clinical oncology. 39 (14), pp. 1584-1594. [Online].